WO2008134088A1 - Hydroxy sulfonate of quinone compounds and their uses - Google Patents
Hydroxy sulfonate of quinone compounds and their uses Download PDFInfo
- Publication number
- WO2008134088A1 WO2008134088A1 PCT/US2008/005656 US2008005656W WO2008134088A1 WO 2008134088 A1 WO2008134088 A1 WO 2008134088A1 US 2008005656 W US2008005656 W US 2008005656W WO 2008134088 A1 WO2008134088 A1 WO 2008134088A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lapachone
- pharmaceutical composition
- compound
- bisulfite
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention provides sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro-2H- benzo( ⁇ )chromene-6-sulfonate, and its synthesis and uses in the treatment of cancer.
- Quinones are a group of aromatic dioxo compounds derived from benzene or multiple-ring hydrocarbons such as naphthalene, anthracene, etc. They are classified as benzoquinones, naphthoquinones, anthraquinones, etc., on the basis of the ring system. Quinones are found in all major groups of organisms as a large and varied group of natural products. Quinones have a variety of medicinal and industrial uses.
- antineoplastic drugs are either quinones (anthracycline derivatives, mitoxantrone, actinomycin), quinonoid derivatives (quinolones, genistein, bactracyclin), or drugs such as etoposide that can easily be converted to quinones by in vivo oxidation (Gantchev et al. (1997) Biochem. Biophys. Res. Comm. 237:24-27). Quinones are now widely used as anti-cancer, anti-bacterial and anti-malarial drugs, as well as fungicides.
- ⁇ -lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[l,2-b]pyran-5,6-dione) is a quinone derived from lapachol (a naphthoquinone).
- Lapachol can be isolated from the lapacho tree (Tabebuia avellanedae), a member of the catalpa family (Bignoniaceae).
- Lapachol and ⁇ -lapachone (with numbering) have the following chemical structures:
- Lapachol ⁇ -Lapachone ⁇ -lapachone as well as its intermediates, derivatives and analogs thereof, are described in Li, CJ. et al, (1993) J. Biol. Chem., 268(30): 22463-22468.
- ⁇ -lapachone As a single agent, ⁇ -lapachone has demonstrated significant antineoplastic activity against human cancer cell lines at concentrations typically in the range of 1-10 ⁇ M (IC 50 ).
- E2F1 independent of DNA damage and cell cycle stages.
- ⁇ -lapachone activates checkpoint pathways and induces cell death in cancer cells from a variety of tissues without causing death of normal cells from these tissues.
- a checkpoint molecule results in a transient expression pattern and causes little consequence.
- cancer and pre-cancer cells have defective mechanisms.
- Drug-induced elevation of checkpoint molecules, e.g. E2F1 can lead to selective cell death in these disregulated cells.
- PCT Application PCT/US06/20780 discloses tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells.
- the naphthoquinone derivatives of the present invention are related to ⁇ - lapachone.
- WO 2006/128120 discloses sulfur analogs and derivatives of ⁇ -lapachone as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders.
- quinones In addition to their antineoplastic uses, quinones also have a number of other medicinal uses.
- Terpenoid-type quinones are also useful as treatments for diabetes.
- Hydroquinone amines and quinone amines are also useful for treating a number of conditions, including spinal trauma and head injury.
- Degenerative central nervous system diseases, as well as vascular diseases are treatable with quinones such as Idebenone [2,3- dimethoxy-5-methyl-6-(10-hydroxydecyl)-l,4-benzoquinone] and Rifamycin (S. Mordente etal (1998) Chem. Res. Toxicol. 11 :54-63; Rao et al (1997) Free Radic. Biol. Med 22:439-46; Cortelli et al. (1997) J. Neurol Sd. 148:25-31; and Mahadik et al.
- Quinones such as aloin, a C-glycoside derivative of anthraquinone, accelerate ethanol oxidation and may be useful in treating acute alcohol intoxication. (Chung et al. (1996) Biochem. Pharmacol. 52:1461-8 and Nanji et al (1996) Toxicol. Appl Pharmacol. 140:101-7). Quinones capsaicin and resiniferatoxin blocked activation of nuclear transcription factor NF- ⁇ B, which is required for viral replication, immune regulation and induction of various inflammatory and growth- regulatory genes (Singh et al. (1996) J. Immunol 157:4412-20). Antiretroviral and antiprotozoan naphthoquinones are described in U.S. Pat. Nos.
- U.S. Pat. No. 6,962,944 and 7,074,824 disclose pharmaceutical compositions comprising a therapeutically effective amount of ⁇ -lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be a water-solubilizing carrier molecule such as hydroxypropyl- ⁇ -cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of ⁇ -lapachone in aqueous solution.
- the therapeutically effective amount of ⁇ -lapachone, or a derivative or analog thereof may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution.
- WO 2006/020719 discloses quinone prodrug compositions and therapeutic methods using such prodrug compositions.
- the quinone compounds of the invention are preferably naphthoquinone compounds such as ⁇ -lapachone or ⁇ -lapachone analogs.
- the quinone prodrug compositions exhibit improved solubility, stability, bioavailability, and pharmacokinetic properties, as well as improved plasma half-life in vivo. There is still a need for improved formulations of quinone compounds for pharmaceutical administration, which are both safe and readily bioavailable to the subject to which the formulation is administered.
- the present invention provides a compound of formula I:
- G is a cation.
- the G can be a metal cation, such as H + , Na + , K + , Li + , or Ca 2+ .
- the compond of claim 1 wherein the G is N + (Ri) 4 , wherein each Ri is independently selected from the group consisting of H, C 2 -C 6 straight alkyl, C 3 -C 6 branched alkyl, C 3 -C 8 cycloalkyl, C 5 -C 8 cycloalkenyl, phenyl, C 5 -C 8 aryl, and benzyl.
- the compond of formula I is 1) or a pharmaceutically acceptable salt and/or an individual enantiomer/diastereomer thereof.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of formula I.
- the pharmaceutical composition further comprises a pharmaceutically acceptable solubilizing carrier molecule, such as cyclodextrin, substituted cyclodextrin, ⁇ -cyclodextrin, or hydroxy propyl - ⁇ - cyclodextrin (HP ⁇ CD).
- a pharmaceutically acceptable solubilizing carrier molecule such as cyclodextrin, substituted cyclodextrin, ⁇ -cyclodextrin, or hydroxy propyl - ⁇ - cyclodextrin (HP ⁇ CD).
- the present invention also provides a method of treating a cell proliferative disorder.
- the method comprises administering to a subject in need thereof a therapeutically effective amount of the compound of formula I, or a pharmaceutically acceptable salt thereof, or a prodrug or metabolite thereof, in combination with a pharmaceutically acceptable carrier, wherein said cell proliferative disorder is treated.
- the cell proliferative disorder is either a precancerous condition or a cancer, such as adenocarcinoma, squamous carcinoma, sarcoma, lymphoma, multiple myeloma, leukemia, lung cancer, colon cancer, breast cancer, pancreatic cancer, prostate cancer, acute leukemia, chronic leukemia, multiple melanoma, ovarian cancer, malignant glioma, leiomyosarcoma, hepatoma, or head and neck cancer.
- a cancer such as adenocarcinoma, squamous carcinoma, sarcoma, lymphoma, multiple myeloma, leukemia, lung cancer, colon cancer, breast cancer, pancreatic cancer, prostate cancer, acute leukemia, chronic leukemia, multiple melanoma, ovarian cancer, malignant glioma, leiomyosarcoma, hepatoma, or head and neck cancer.
- the compound of formula I, or a pharmaceutically acceptable salt thereof, or a prodrug or metabolite thereof, can be administered in combination with a second chemotherapeutic agent.
- the present invention also provides a synthetic process.
- the process comprises mixing a quinone compound, or a derivative or an analog thereof, and a bisulfite agent.
- the quinone compound can be an ortho-quinone compound, a tetra-substituted ortho-quinone compound, or ⁇ - lapachone, or a derivative or analog thereof.
- bisulfite agent is a source of bisulfite in an aqueous solution, which is capable of producing HSO 3 " in aqueous solution.
- the bisulfite agent can be metabisulfite salt, bisulfite salt, or dithionite salt.
- the present invention further provides a compound prepared by the process.
- the present invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of ⁇ -lapachone, or a derivative or analog thereof, and a chemical agent selected from the group consisting of metabisulfite salt, bisulfite salt, and dithionite salt.
- the pharmaceutical composition can further comprise a pharmaceutically acceptable solubilizing carrier molecule, such as alpha, beta and gamma cyclodextrin, substituted cyclodextrins like sulfobutyl ether (SBE), beta-cyclodextrin, or HP ⁇ CD.
- a pharmaceutically acceptable solubilizing carrier molecule such as alpha, beta and gamma cyclodextrin, substituted cyclodextrins like sulfobutyl ether (SBE), beta-cyclodextrin, or HP ⁇ CD.
- the present invention also provides a method of improving the solubility of quinone compound comprising mixing a quinone compound, or a derivative or an analog thereof, and a chemical agent that is source of bisulfite in an aqueous solution.
- the quinone compound can be an ortho-quinone compound, a tetra-substituted ortho-quinone compound, ⁇ -lapachone, or a derivative or analog thereof.
- the present invention provides a pharmaceutical composition, which comprises ⁇ -lapachone in the form of crystalline particles wherein 90% of the particles have a diameter of 100 ⁇ m or lower, 30 ⁇ m or lower, or 10 ⁇ m or lower.
- the pharmaceutical composition can further comprise a particle carrier such as lactose or mannitol.
- the pharmaceutical composition can further comprise a bisulfite agent.
- the ⁇ -lapachone composition can by sterilized with the means such as gamma radiation.
- the present invention provides a kit for the treatment of a mammalian tumor.
- the kit comprises a first container containing a ⁇ -lapachone composition, and a second container containing a bisulfite agent.
- the ⁇ -lapachone composition comprises ⁇ -lapachone in the form of crystalline particles wherein 90% of the particles have a diameter of 30 ⁇ m or lower, or 10 ⁇ m or lower.
- the ⁇ -lapachone composition can further comprise a particle carrier, such as lactose or mannitol.
- the bisulfite agent is selected from the group consisting of metabisulf ⁇ te salt such as sodium metabisulfite, bisulfite salt such as sodium bisulfite, and dithionite salt.
- Figures IA through 1C show the effect of bisulfite on the solubility of ⁇ -lapachone.
- Figure IA shows the effect of sodium metabisulfite.
- Figure IB shows the effect of sodium bisulfite.
- Figure 1C shows the effects of sodium metabisulfite, sodium bisulfite, and sodium dithionite.
- Figure 2A shows a unit cell from the X-ray structure of 6-hydroxy-2,2-dimethyl-5-oxo- 3 ,4,5 ,6-tetrahydro-2H-benzo( ⁇ )chromene-6-sulfonate.
- Figure 2B shows the structure of sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro- 2H-benzo( ⁇ )chromene-6-sulfonate (I) with atoms labeled.
- Figure 3 shows overlay of the UV-vis spectra of the ⁇ -lapachone and hydroxy sulfonate of ⁇ - lapachone.
- Figure 4 shows the effect of methyl ⁇ cyclodextrin (Me ⁇ CD) on the solubility of ⁇ - lapachone.
- the present invention provides a compound of formula I: or a pharmaceutically acceptable salt and/or an individual enantiomer/diastereomer thereof; wherein G is a cation.
- the G can be a metal cation.
- the G can be selected from the group consisting of H + , Na + , K + , Li + , and Ca 2+ .
- the G can be N + (R ⁇ 4 , wherein each Ri is independently selected from the group consisting of H, C 2 -C 6 straight alkyl, C 3 -C 6 branched alkyl, C 3 -C 8 cycloalkyl, Cs-C 8 cycloalkenyl, phenyl, C 5 -C 8 aryl, and benzyl.
- the compond of the present invention is compound 1 :
- the purity of the compound of formula I or Compound 1 can be 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, or 99% or more.
- the purity of the compound of formula I or Compound 1 refers to the percentage of the hydroxy sulfonate of ⁇ -lapachone in total ⁇ -lapachone (i.e., hydroxy sulfonate of ⁇ -lapachone and ⁇ -lapachone).
- the compound of formula I or Compound 1 can be isolated as a solid in crystalline form, lyophilized form, or aqueous form.
- the crystalline form or lyophilized form of the compound of formula I or Compound 1 can be reconstituted.
- the compound of formula I or Compound 1 can revert back to ⁇ -lapachone in certain conditions, including dilution at physiological pH, or in plasma of humans or other mammals.
- the present invention also provides a synthetic process.
- the process comprises mixing a quinone compound, or a derivative or an analog thereof, and a bisulfite agent.
- the quinone compound can be an ortho-quinone compound or a tetra-substiruted ortho- quinone compound.
- the quinone compound is ⁇ -lapachone, or a derivative or analog thereof.
- the quinone compound is ⁇ -lapachone.
- the bisulfite agent is a chemical agent that is a source of bisulfite in an aqueous solution, which is capable of producing HSO 3 " in aqueous solution.
- the bisulfite agent is capable of converting quinones to hydroxy sulfonates as in compound 1.
- Such a bisulfite agent can be selected from the group consisting of metabisulfite salt, bisulfite salt, and dithionite salt.
- the chemical agent can be sodium metabisulfite, or sodium bisulfite.
- Sodium metabisulfite Na 2 O 5 S 2 , CAS # 7681- 57-4
- sodium bisulfite HNaO 3 S, CAS 7631-90-5
- sodium dithionite Na 2 S 2 O 4 , CAS # 7775-14- 6
- the bisulfite agent is capable of converting the quinone compound to a hydroxy sulfonate of a quinone compound.
- the resulting hydroxy sulfonate of the quinone compound is more soluble than the quinone compound.
- the hydroxy sulfonate of the quinone compound can revert back to the quinone compound.
- the pH of the aqueous solution for the preparation of the compound of the present invention is 7 or lower, 6 or lower, 5 or lower, 4 or lower, or 3 or lower.
- the molar ratio of the HSO 3 " to ⁇ -lapachone is 4 or less, 3 or less, 2 or less, or 1 or less.
- compositions are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components.
- methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps.
- steps or order for performing certain actions is immaterial so long as the invention remains operable.
- two or more steps or actions can be conducted simultaneously.
- the synthetic processes of the invention can tolerate a wide variety of functional groups, therefore various substituted starting materials can be used.
- the processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt, ester, or prodrug thereof.
- the compounds of this invention with general formula (I) may be prepared according to the following scheme from commercially available starting material or starting materials, which can be prepared using literature procedures. These schemes show the preparation of representative compounds of this invention.
- the present invention also provides methods for the synthesis of the compounds of Formula I.
- the present invention provides a method for the synthesis of compounds according to the following schemes, and the protocols shown in the Examples.
- the compounds of Formula I can be prepared from the reaction of 2,2- dimethyl-2,3-dihydro-2H-benzo( ⁇ )chromene-5,6-dione ( ⁇ -lapachone) and appropriate intermediate/commercial reagents. (Scheme 1)
- ⁇ -lapachone can be conveniently prepared by a variety of methods familiar to those skilled in the art. (see, e.g., US Pat. No. 6,458,974, for the synthesis of ⁇ -lapachone).
- the hydroxy sulfonates (I) can be conveniently prepared by treating quinones especially ortho-quinones with reagents that are sources of nucleophilic bisulfites such as sodium metabisulfite, sodium hydrogensulf ⁇ te, sodium dithionite, potassium metabisulfite including bisulfite sources with different metal and substituted and unsubstituted ammonium cations.
- the particle size of ⁇ -lapachone plays an important role in the reaction rate for the formation of Compound 1.
- ⁇ -lapachone causes the reaction with the bisulfite to occur faster by decreasing the time needed to dissolve ⁇ -lapachone. For example when ⁇ -lapachone contains large particles (e.g., 90% less than 400-500 ⁇ m), it takes a minimum of 18 hours for the reaction to go to completion. However, when ⁇ -lapachone is micronized (e.g., 90% of the particles are below 10 ⁇ m), the conversion occurs rapidly (e.g., in about 1 minute).
- the present invention provides a ⁇ -lapachone composition, which comprises ⁇ -lapachone in the form of crystalline particles with small particle size.
- 90% of the particles have a diameter of 200 ⁇ m or lower, 100 ⁇ m or lower, 30 ⁇ m or lower, or 10 ⁇ m or lower.
- the ⁇ - lapachone composition can further comprise a particle carrier such as lactose or mannitol.
- the ⁇ - lapachone composition can by sterilized with the means such as gamma radiation.
- the crystalline ⁇ -lapachone can be micronized using various means known in the field, such as air-jet milling, and ball milling.
- the conversion rate also depends on the amount of energy used for the mixing. When high energy (e.g., ultrasonic energy) is used, the conversion is complete within several minutes regardless of the particle size.
- high energy e.g., ultrasonic energy
- the hydroxy sulfonate (I) can be isolated as a crystalline solid, a lyophilized solid, or as a solution.
- the hydroxy sulfonate (I) obtained as a lyophilized powder can be dissolved in water, DMSO, acetonitrile/water mixtures (1:1 to 1:3), etc.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the present invention such as the compound of formula I or compound 1.
- the concentration of the compound of the present invention is in the range from 0.0001 M to 0.2 M, 0.001 M to 0.1 M, 0.01 M to 0.1 M, 0.02 M to 0.09 M, 0.03 M to 0.08M, 0.04 M to 0.07 M, or 0.05 M to 0.06 M.
- the pharmaceutical composition can be provided to the end user in a number of forms.
- the pharmaceutical composition is a sterile solution, which is further diluted with an acceptable fluid for intravenous administration.
- the pharmaceutical composition can comprise a combination of antioxidants and co-solvents.
- the pharmaceutical composition can further comprise a dextrose solution or a combination of dextrose and a buffer such as sodium acetate buffer, for the purpose of intravenous administration.
- the pH of the pharmaceutical composition can be from 3 to 6. In an embodiment, the pH is 5.
- the antioxidant can be such as sodium thiosulfate, ethylene diamine tetraacetic acid (EDTA), or Butylated hydroxytoluene (BHT).
- EDTA ethylene diamine tetraacetic acid
- BHT Butylated hydroxytoluene
- the pharmaceutical composition of the present invention can further comprise a pharmaceutically acceptable solubilizing carrier molecule.
- the solubilizing carrier molecule can be cyclodextrin or substituted cyclodextrin.
- the solubilizing carrier molecule can also be ⁇ -cyclodextrin, ⁇ -cyclodextrin or ⁇ -cyclodextrin.
- the solubilizing carrier molecule is HP ⁇ CD.
- the concentration of HP ⁇ CD is in the range from 0.1% to 20%, 0.5% to 10%, 1% to 6%, or 2% to 5%.
- the pharmaceutical composition can also comprise polyethylene glycol (PEG) or ethanol or both.
- the pharmaceutical composition is in solid form, which can be dissolved with water or a buffer.
- the pharmaceutical composition comprises ⁇ -lapachone in the form of crystalline particles wherein 90% of the particles have a diameter of 30 ⁇ m or lower, or 10 ⁇ m or lower, and a bisulfite agent.
- the bisulfite agent can be selected from the group consisting of metabisulfite salt such as sodium metabisulf ⁇ te, bisulfite salt such as sodium bisulfite, and dithionite salt.
- the pharmaceutical composition can further comprise a particle carrier such as lactose or mannitol. Alternatively, the particle carrier can be the bisulfite agent.
- the pharmaceutical composition can by sterilized with the means such as gamma radiation.
- the product could be a kit containing two independent primary containers such as vials.
- the two respective vials would contain: (1) ⁇ -lapachone as a micronized or milled solid mixed with suitable excipients and (2) a solution containing a reagent (that is a source of bisulfite) in a buffer, ⁇ -lapachone could be terminally sterilized by gamma radiation or other means of sterilization.
- the bisulfite solution could be terminally sterilized by sterile filtration or steam sterilization.
- Compound 1 is prepared prior to administration by adding the bisulfite solution to the vial containing ⁇ -lapachone and mixing for several minutes until ⁇ -lapachone completely dissolves and is converted by the source of bisulfite to compound 1.
- the present invention provides a kit for the treatment of a mammalian tumor.
- the kit comprises a first container containing a ⁇ -lapachone composition, and a second container containing a bisulfite agent.
- the ⁇ -lapachone composition comprises ⁇ -lapachone in the form of crystalline particles wherein 90% of the particles have a diameter of 30 ⁇ m or lower, or 10 ⁇ m or lower.
- the ⁇ -lapachone composition can further comprise a particle carrier, such as lactose particle or mannitol particle.
- the bisulfite agent is selected from the group consisting of metabisulfite salt such as sodium metabisulfite, bisulfite salt such as sodium bisulfite, and dithionite salt.
- the bisulfite agent is in a solution comprising a buffer.
- the solution can further comprise an antioxidant.
- Both the ⁇ -lapachone composition and the bisulfite agent can be sterilized.
- the ⁇ -lapachone composition can be sterilized with gamma radiation.
- the bisulfite reagent in solution can be sterilized with sterile filtration or steam sterilization.
- the kit further comprises a conduit connecting the first container and the second container.
- the conduit can comprise a valve.
- the kit may comprise instructions how to make compound 1 by mixing the ⁇ -lapachone composition and the bisulfite agent, how to administer the compound 1.
- a “pharmaceutically acceptable salt” or “salt” of the disclosed compound is a product of the disclosed compound that contains an ionic bond, and is typically produced by reacting the disclosed compound with either an acid or a base, suitable for administering to a subject.
- Pharmaceutically acceptable salt can include, but is not limited to, acid addition salts including hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates, and tartrates; alkali metal cations such as Na, K, Li, alkali earth metal salts such as Mg or Ca, or organic amine salts.
- a “pharmaceutical composition” is a formulation containing the disclosed compounds in a form suitable for administration to a subject.
- the pharmaceutical composition is in bulk or in unit dosage form.
- the unit dosage form is any of a variety of forms, including, for example, a capsule, an FV bag, a tablet, a single pump on an aerosol inhaler, or a vial.
- the quantity of active ingredient (e.g., a formulation of the disclosed compound or salts thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved.
- active ingredient e.g., a formulation of the disclosed compound or salts thereof
- the dosage will also depend on the route of administration.
- routes including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, intranasal, and the like.
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.
- the present invention also provides pharmaceutical formulations comprising a compound of
- Formula I in combination with at least one pharmaceutically acceptable excipient or carrier.
- pharmaceutically acceptable excipient or “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in "Remington: The Science and Practice of Pharmacy, Twentieth Edition," Lippincott Williams & Wilkins, Philadelphia, PA., which is incorporated herein by reference. Examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin.
- Liposomes and non-aqueous vehicles such as fixed oils may also be used.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- a compound of Formula I is administered in a suitable dosage form prepared by combining a therapeutically effective amount (e.g., an efficacious level sufficient to achieve the desired therapeutic effect through inhibition of tumor growth, killing of tumor cells, treatment or prevention of cell proliferative disorders, etc.) of a compound of Formula I (as an active ingredient) with standard pharmaceutical carriers or diluents according to conventional procedures (i.e., by producing a pharmaceutical composition of the invention). These procedures may involve mixing, granulating, and compressing or dissolving the ingredients as appropriate to attain the desired preparation.
- a therapeutically effective amount of a compound of Formula I is administered in a suitable dosage form without standard pharmaceutical carriers or diluents.
- Pharmaceutically acceptable carriers include solid carriers such as lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
- Exemplary liquid carriers include syrup, peanut oil, olive oil, water and the like.
- the carrier or diluent may include time-delay material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like.
- Other fillers, excipients, flavorants, and other additives such as are known in the art may also be included in a pharmaceutical composition according to this invention.
- compositions containing active compounds of the present invention may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
- Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and/or auxiliaries which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.
- a compound or pharmaceutical composition of the invention can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment.
- a compound of the invention may be injected directly into tumors, injected into the blood stream or body cavities or taken orally or applied through the skin with patches.
- systemic administration e.g., oral administration
- topical administration to affected areas of the skin are preferred routes of administration.
- the dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects.
- the state of the disease condition e.g., cancer, psoriasis, and the like
- the health of the patient should be closely monitored during and for a reasonable period after treatment.
- the compounds of formula I can convert back to ⁇ -lapachone, which has significant antineoplastic activity against various human cancer cells.
- the present invention also provides a method for the treatment of a cell proliferative disorder in a mammal comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of the present invention such as a compound of Formula I.
- the invention further provides the use of a compound of Formula I for the preparation of a medicament useful for the treatment of a cell proliferative disorder.
- the invention provides for the treatment of cancer or precancerous conditions in a mammal comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of Formula I.
- the mammal can be e.g., any mammal, e.g., a human, a primate, mouse, rat, dog, cat, cow, horse, pig.
- the mammal is a human.
- An effective amount of a compound of Formula I is used in a method to treat a cell proliferative disorder in a mammal without affecting normal cells of the mammal.
- a therapeutically effective amount of a compound of Formula I is used in a method for treating cancer in a mammal by inducing cell death in cancer cells without affecting normal cells in the mammal. Cell death can occur by either apoptosis or necrosis mechanisms.
- administration of a therapeutically effective amount of a compound of Formula I induces sustained (non-transient) activity (e.g. elevation of the level) of a checkpoint molecule in abnormally proliferating cells without affecting checkpoint molecule activity in normal cells.
- administration of a therapeutically effective amount of a compound of Formula I induces activation of E2F1 checkpoint pathway in abnormally proliferating cells without significantly affecting normal cells.
- administration induces sustained E2F pathway activity (e.g. elevation of E2F levels) in cancer cells without affecting E2F pathway activity (e.g. E2F levels) in normal cells.
- sustained E2F pathway activity e.g. elevation of E2F levels
- E2F pathway activity e.g. E2F levels
- Methods of measuring induction of E2F activity and elevation of E2F levels are as shown in Li et al., (2003) Proc Natl Acad Sd USA. 100(5): 2674-8.
- administration of a therapeutically effective amount of a compound of Formula I induces cell death in abnormally proliferating cells without inducing cell death in normal cells.
- the invention also provides a method of protecting against a cell proliferative disorder in a mammal by administering a therapeutically effective amount of a compound of Formula I to a mammal.
- the invention also provides the use of a compound of Formula I for the preparation of a medicament useful for the prevention of a cell proliferative disorder.
- the invention provides for the prevention of cancer in a mammal comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of Formula I.
- the compounds of the invention are administered in the form of pharmaceutical compositions, e.g., as described herein.
- a "subject” can be any mammal, e.g., a human, a primate, mouse, rat, dog, cat, cow, horse, pig, sheep, goat, camel. In a preferred aspect, the subject is a human.
- a "subject in need thereof is a subject having a cell proliferative disorder, or a subject having an increased risk of developing a cell proliferative disorder relative to the population at large.
- a subject in need thereof has a precancerous condition.
- a subject in need thereof has cancer.
- the term "cell proliferative disorder” refers to conditions in which the unregulated and/or abnormal growth of cells can lead to the development of an unwanted condition or disease, which can be cancerous or non-cancerous, for example a psoriatic condition.
- psoriatic condition refers to disorders involving keratinocyte hyperproliferation, inflammatory cell infiltration, and cytokine alteration.
- the cell proliferation disorder is cancer.
- cancer includes solid tumors, such as lung, breast, colon, ovarian, prostate, malignant melanoma, non-melanoma skin cancers, as well as hematologic tumors and/or malignancies, such as childhood leukemia and lymphomas, multiple myeloma, Hodgkin's disease, lymphomas of lymphocytic and cutaneous origin, acute and chronic leukemia such as acute lymphoblastic, acute myelocytic or chronic myelocytic leukemia, plasma cell neoplasm, lymphoid neoplasm and cancers associated with AIDS.
- solid tumors such as lung, breast, colon, ovarian, prostate, malignant melanoma, non-melanoma skin cancers, as well as hematologic tumors and/or malignancies, such as childhood leukemia and lymphomas, multiple myeloma, Hodgkin's disease, lymphomas of lymphocytic and cutaneous origin, acute and chronic leukemia such as acute
- proliferative diseases which may be treated using the compositions of the present invention are epidermic and dermoid cysts, lipomas, adenomas, capillary and cutaneous hemangiomas, lymphangiomas, nevi lesions, teratomas, nephromas, myofibromatosis, osteoplastic tumors, and other dysplastic masses and the like.
- proliferative diseases include dysplasias and disorders of the like.
- monotherapy refers to administration of a single active or therapeutic compound to a subject in need thereof.
- monotherapy will involve administration of a therapeutically effective amount of an active compound.
- cancer monotherapy with one of the compounds of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, to a subject in need of treatment of cancer.
- Monotherapy may be contrasted with combination therapy, in which a combination of multiple active compounds is administered, preferably with each component of the combination present in a therapeutically effective amount.
- montherapy with a compound of the present invention is more effective than combination therapy in inducing a desired biological effect.
- treating describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present invention to alleviate the symptoms or complications, or eliminate the disease, condition or disorder.
- preventing describes the administration of a compound of the present invention to prevent the onset of the symptoms or complications of a disease, condition, or disorder.
- treating cancer results in a reduction in the size of a tumor.
- treating cancer results in a reduction in tumor volume.
- treating cancer results in a decrease in number of tumors.
- treating cancer results in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site.
- treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone. In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects. In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof. In another aspect, treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone. In another aspect, treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population.
- treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof.
- treating cancer results in a decrease in tumor growth rate.
- treating cancer results in a decrease in tumor regrowth.
- treating or preventing a cell proliferative disorder results in a reduction in the rate of cellular proliferation.
- treating or preventing a cell proliferative disorder results in a reduction in the proportion of proliferating cells.
- treating or preventing a cell proliferative disorder results in a decrease in the size of an area or zone of cellular proliferation.
- treating or preventing a cell proliferative disorder results in a decrease in the number or proportion of cells having an abnormal appearance or morphology.
- a compound of the present invention or a pharmaceutically acceptable salt, metabolite, analog or derivative thereof, can be administered in combination with a chemotherapeutic agent.
- chemotherapeutic agents with activity against cell proliferative disorders are known to those of ordinary skill in the art, and may be found in reference texts such as the Physician's Desk Reference, 59 th Edition, Thomson PDR (2005).
- the chemotherapeutic agent can be a taxane, an aromatase inhibitor, an anthracycline, a microtubule targeting drug, a topoisomerase poison drug, a targeted monoclonal or polyclonal antibody, an inhibitor of a molecular target or enzyme (e.g., a kinase inhibitor), or a cytidine analogue drug.
- the chemotherapeutic agent can be, but is not restricted to, tamoxifen, raloxifene, anastrozole, exemestane, letrozole, cisplatin, carboplatin, TAXOL ® (paclitaxel), cyclophosphamide, lovastatin, minosine, GEMZAR ® (gemcitabine HCl), cytarabine (araC), 5-fluorouracil (5-FU), methotrexate (MTX), TAXOTERE ® (docetaxel), ZOLADEX ® (goserelin), vincristin, vinblastin, nocodazole, teniposide, etoposide, epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin (adriamycin), epirubicin,
- the chemotherapeutic agent can be a cytokine such as G-CSF (granulocyte colony stimulating factor), hi another aspect, ⁇ -lapachone, or a pharmaceutically acceptable salt, metabolite, analog or derivative thereof may be administered in combination with radiation therapy.
- ⁇ -lapachone, or a pharmaceutically acceptable salt, metabolite, analog or derivative thereof may be administered in combination with standard chemotherapy combinations such as, but not restricted to, CMF (cyclophosphamide, methotrexate and 5-fluorouracil), CAF
- chemotherapeutic agents can be found in WO/2004/006849.
- Example 1 Bisulfite improves the solubility of ⁇ -lapachone in aqueous solution
- Solutions of bisulfites at different concentrations were prepared in water or 2.5% HP ⁇ CD and an excess amount of ⁇ -lapachone was added to obtain a saturated solution. These solutions were shaken for 24 hours, filtered through a 0.45 ⁇ m filter, and analyzed for ⁇ -lapachone concentration by HPLC.
- Example 2 Sodium metabisulfite converts ⁇ -lapachone to sodium 6-hydroxy-2.2-dimethyl-5-oxo- 3.4.5.6-tetrahydro-2//-benzo( ' /»)chromene-6-sulfonate
- Example 3 The reversion of the compound 1 to ⁇ -lapachone
- compound 1 sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6- tetrahydro-2H-benzo(A)chromene-6-sulfonate, reverts back to ⁇ -lapachone.
- ⁇ PLC analysis of the formulation shows that the only species present is ⁇ -lapachone even though the color of the formulation becomes lighter depending on the amount of bisulfites added. The results indicate that compound 1 reverts back to ⁇ -lapachone under the conditions of sample preparation for ⁇ PLC analysis.
- the compound can be prepared at different concentrations (0.01-0.1 M ) depending on the amount of sodium metabisulfite, sodium bisulfite or sodium dithionite added. (See Fig. 1C)
- ⁇ -lapachone 750 mg was added to 50 mL of an aqueous solution containing 20 mg/mL Na 2 S 2 O 5 and 5% mannitol. The solution was mixed for 18 hours at room temperature, and filtered through a 0.45 ⁇ m PVDF filter and lyophilized. The lyophilized solid can be reconstituted with water or 5% dextrose.
- Reagent Na 2 S 2 O 5 , Na 2 S 2 O 4 , or NaHSO 3
- the hydroxy sulfonate of ⁇ -lapachone easily reverts back to ⁇ -lapachone in dilute solutions of bisulfite and other reagents.
- a solution of Compound 1 is diluted with a mobile phase containing acetonitrile and phosphate buffer at pH 6.8 and analyzed by HPLC, only the ⁇ - lapachone can be detected.
- the mass by LC/MS for Compound 1 can be obtained using a short LC method where the acetonitrile/water mobile phase is acidified with 0.1% formic acid. Even under these conditions, two peaks are observed, one peak corresponding to Compound 1, and one to the ⁇ -lapachone released from the complex.
- UV-vis spectra of ⁇ -lapachone solutions in water and HP ⁇ CD exhibit an absorbance maximum at 256 ran and one smaller absorbance band at 213 nm.
- the UV absorbance maxima for Compound 1 are shifted to 233 nm and 327 nm. (See Fig. 3).
- Table E Maximum concentrations of ⁇ -lapachone converted at different pHs.
- Example 7 The effects of sodium bisulfite and sodium metabisulfite on the solubility of derivatives or analogs of ⁇ -lapachone
- Example 8 The effect of Me ⁇ CD on the solubility of ⁇ -lapachone
- Methyl beta-cyclodextrin is a derivative of beta-cyclodextrin with 1-7 methyl substituents on the secondary 0-2 positions.
- the solubility of ⁇ -lapachone is significantly enhanced in the presence of Me ⁇ CD.
- the equilibrium solubility is directly proportional to the amount of Me ⁇ CD as illustrated in Fig. 4.
- the average degree of substitution (DS) has an influence on the complexing abilities of the cyclodextrin derivatives. Cyclodextrin derivatives with low DS are better solubilizing agents than cyclodextrins with high DS.
- Example 9 A solution formulation of compound 1 Compound 1 was made under the conditions as follows:
- the pH of the formulated product with sodium acetate buffer is 5.
- the pH of the mixture of ⁇ -lapachone and sodium metabisulfite or sodium bisulfite is 3.
- the particle size of the milled ⁇ -lapachone was measured by laser diffraction technique using a Mastersizer 2000 (Malvern Instruments).
- the Dv (0.9) of the milled material is in the range of 140- 150 ⁇ m.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES08754188.4T ES2532656T3 (en) | 2007-04-30 | 2008-04-30 | Quinone hydroxy sulfonate compounds and their uses |
BRPI0810717A BRPI0810717A2 (en) | 2007-04-30 | 2008-04-30 | hydroxy sulfonate of quinone compound and its uses |
DK08754188.4T DK2152686T3 (en) | 2007-04-30 | 2008-04-30 | HYDROXYSULFONAT OF quinone compounds AND THEIR USES |
EP08754188.4A EP2152686B1 (en) | 2007-04-30 | 2008-04-30 | Hydroxy sulfonate of quinone compounds and their uses |
AU2008246067A AU2008246067B2 (en) | 2007-04-30 | 2008-04-30 | Hydroxy sulfonate of quinone compounds and their uses |
CN200880022708.XA CN101687835B (en) | 2007-04-30 | 2008-04-30 | The hydroxy sulfonate of quinone compounds and their application |
JP2010506326A JP2010526072A (en) | 2007-04-30 | 2008-04-30 | Hydroxysulfonate of quinone compound and use thereof |
MX2009011822A MX2009011822A (en) | 2007-04-30 | 2008-04-30 | Hydroxy sulfonate of quinone compounds and their uses. |
CA2685739A CA2685739C (en) | 2007-04-30 | 2008-04-30 | Hydroxy sulfonate of quinone compounds and their uses |
HK10106231.4A HK1139411A1 (en) | 2007-04-30 | 2010-06-24 | Hydroxy sulfonate of quinone compounds and their uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91497107P | 2007-04-30 | 2007-04-30 | |
US60/914,971 | 2007-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008134088A1 true WO2008134088A1 (en) | 2008-11-06 |
Family
ID=39494644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/005656 WO2008134088A1 (en) | 2007-04-30 | 2008-04-30 | Hydroxy sulfonate of quinone compounds and their uses |
Country Status (14)
Country | Link |
---|---|
US (1) | US7790765B2 (en) |
EP (1) | EP2152686B1 (en) |
JP (1) | JP2010526072A (en) |
KR (1) | KR20100017483A (en) |
CN (1) | CN101687835B (en) |
AU (1) | AU2008246067B2 (en) |
BR (1) | BRPI0810717A2 (en) |
CA (1) | CA2685739C (en) |
DK (1) | DK2152686T3 (en) |
ES (1) | ES2532656T3 (en) |
HK (1) | HK1139411A1 (en) |
MX (1) | MX2009011822A (en) |
TW (1) | TWI401081B (en) |
WO (1) | WO2008134088A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009048251A2 (en) * | 2007-10-11 | 2009-04-16 | Mazence Inc. | Pharmaceutical composition containing micronized particles of naphthoquinone-based compound |
KR101405823B1 (en) * | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | Pharmaceutical Composition for the Treatment and Prevention of glaucoma |
KR20090071829A (en) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | Pharmaceutical composition for treatment and prevention of kidney diseases |
WO2012104241A1 (en) | 2011-01-31 | 2012-08-09 | LUCOLAS-M.D. Ltd | Combinations of aromatase inhibitors and antioxidants |
US9343930B2 (en) * | 2012-05-25 | 2016-05-17 | Baldor Electric Company | Segmented stator assembly |
EP3590777B1 (en) * | 2014-07-10 | 2023-01-18 | Robert Bosch GmbH | Motor module and abs hydraulic unit |
WO2016200934A1 (en) * | 2015-06-08 | 2016-12-15 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Mitochondria-targeted lapachone compounds and uses therefor |
WO2018071761A1 (en) | 2016-10-13 | 2018-04-19 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Mitochondrially targeted parp inhibitor, and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033988A1 (en) * | 1995-04-25 | 1996-10-31 | Wisconsin Alumni Research Foundation | Novel synthesis and use of beta-lapachone analogs |
WO2006020719A2 (en) * | 2004-08-11 | 2006-02-23 | Arqule, Inc. | Aminoacid conjugates of beta - lapachone for tumor targeting |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3175151D1 (en) | 1980-05-21 | 1986-09-25 | Teijin Ltd | Reactive polymer and process for the preparation thereof |
US4963565A (en) | 1986-07-30 | 1990-10-16 | National Jewish Center For Immunology And Respiratory Medicine | In vivo treatment of mycobacterial infections with 6-cyclo octylamino-5,8-quinoline quinone |
US5120843A (en) | 1987-04-27 | 1992-06-09 | Upjohn | Pharmaceutically active amines |
FI102273B (en) | 1989-09-11 | 1998-11-13 | Eisai Co Ltd | Quinone derivatives, their preparation and pharmacological use |
JP3111099B2 (en) | 1991-10-31 | 2000-11-20 | 科学技術振興事業団 | Manufacturing method of water-soluble polymerized drug |
US5559156A (en) | 1993-09-30 | 1996-09-24 | Glaxo Wellcome, Inc. | Method for treating animals infected with Babesia spp. |
WO1994004145A1 (en) | 1992-08-21 | 1994-03-03 | Dana Farber Cancer Institute | Treatment of human viral infections |
US5672607A (en) | 1993-01-29 | 1997-09-30 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral naphthoquinone compounds, compositions and uses thereof |
GB2282384B8 (en) | 1993-08-18 | 1997-09-04 | Europ Economic Community | Drug delivery agents incorporating mitomycin |
EP0640609A1 (en) | 1993-08-24 | 1995-03-01 | Ono Pharmaceutical Co., Ltd. | Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5674900A (en) | 1995-06-06 | 1997-10-07 | Shaman Pharmaceuticals, Inc. | Terpenoid-type quinones for treatment of diabetes |
US6245807B1 (en) | 1995-08-24 | 2001-06-12 | Dana-Farber Cancer Institute | Treatment of human prostate disease |
US5824700A (en) | 1996-02-20 | 1998-10-20 | Wisconsin Alumni Research Foundation | Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth |
CN1304058C (en) | 1996-03-12 | 2007-03-14 | Pg-Txl有限公司 | Water soluble paclitaxel prodrugs |
WO1997041093A1 (en) | 1996-04-30 | 1997-11-06 | Affymax Technologies N.V. | Methods for the synthesis of fmoc protected amines |
US6664288B1 (en) | 1999-04-14 | 2003-12-16 | Dana Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
WO2000066175A2 (en) | 1999-04-30 | 2000-11-09 | Slil Biomedical Corporation | Conjugates as therapies for cancer and prostate diseases |
US6376470B1 (en) | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
CN1607962A (en) | 1999-10-12 | 2005-04-20 | 细胞治疗公司 | Manufacture of polyglutamate-therapeutic agent conjugates |
MXPA02009082A (en) | 2000-03-17 | 2003-12-11 | Cell Therapeutics Inc | Polyglutamic acid-camptothecin conjugates and methods of preparation. |
WO2002058694A2 (en) | 2000-11-07 | 2002-08-01 | Dana-Farber Cancer Institute, Inc. | Method of treating hematologic tumors and cancers using beta lapachone |
US6458974B1 (en) | 2001-01-25 | 2002-10-01 | Cyclis Pharmaceuticals, Inc. | Synthesis of β-lapachone and its intermediates |
US7074824B2 (en) | 2001-07-31 | 2006-07-11 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
US6962944B2 (en) | 2001-07-31 | 2005-11-08 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
CZ293787B6 (en) | 2001-12-20 | 2004-07-14 | Zentiva, A.S. | pH sensitive polymeric conjugates of anthracycline cancerostatic for targeted therapy |
WO2003090710A1 (en) | 2002-04-23 | 2003-11-06 | Case Western Reserve University | Lapachone delivery systems, compositions and uses related thereto |
US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
AU2003251904A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
AR056613A1 (en) | 2002-11-18 | 2007-10-17 | Arqule Inc | COMPOUNDS DERIVED FROM LAPACHONA, ITS PREPARATION AND METHODS OF USING THEM FOR THE TREATMENT OR PREVENTION OF CELLULAR PROLIFERATIVE DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
JP2007523190A (en) | 2004-02-20 | 2007-08-16 | アークル・インコーポレーテツド | Use of β-lapachone for the treatment of lung cancer |
CA2556789A1 (en) | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for treating hematologic tumors |
US8614228B2 (en) | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
WO2006128120A2 (en) | 2005-05-26 | 2006-11-30 | Arqule, Inc. | Novel lapachone compounds and methods of use thereof |
-
2008
- 2008-04-30 JP JP2010506326A patent/JP2010526072A/en not_active Withdrawn
- 2008-04-30 US US12/150,914 patent/US7790765B2/en active Active
- 2008-04-30 CA CA2685739A patent/CA2685739C/en active Active
- 2008-04-30 WO PCT/US2008/005656 patent/WO2008134088A1/en active Application Filing
- 2008-04-30 MX MX2009011822A patent/MX2009011822A/en active IP Right Grant
- 2008-04-30 AU AU2008246067A patent/AU2008246067B2/en active Active
- 2008-04-30 DK DK08754188.4T patent/DK2152686T3/en active
- 2008-04-30 CN CN200880022708.XA patent/CN101687835B/en active Active
- 2008-04-30 EP EP08754188.4A patent/EP2152686B1/en active Active
- 2008-04-30 TW TW097115955A patent/TWI401081B/en active
- 2008-04-30 BR BRPI0810717A patent/BRPI0810717A2/en not_active Application Discontinuation
- 2008-04-30 KR KR1020097024913A patent/KR20100017483A/en not_active Application Discontinuation
- 2008-04-30 ES ES08754188.4T patent/ES2532656T3/en active Active
-
2010
- 2010-06-24 HK HK10106231.4A patent/HK1139411A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033988A1 (en) * | 1995-04-25 | 1996-10-31 | Wisconsin Alumni Research Foundation | Novel synthesis and use of beta-lapachone analogs |
WO2006020719A2 (en) * | 2004-08-11 | 2006-02-23 | Arqule, Inc. | Aminoacid conjugates of beta - lapachone for tumor targeting |
Also Published As
Publication number | Publication date |
---|---|
AU2008246067B2 (en) | 2011-10-20 |
EP2152686A1 (en) | 2010-02-17 |
CN101687835B (en) | 2015-08-19 |
TW200913986A (en) | 2009-04-01 |
HK1139411A1 (en) | 2010-09-17 |
CN101687835A (en) | 2010-03-31 |
AU2008246067A1 (en) | 2008-11-06 |
ES2532656T3 (en) | 2015-03-30 |
US7790765B2 (en) | 2010-09-07 |
CA2685739C (en) | 2016-06-14 |
TWI401081B (en) | 2013-07-11 |
MX2009011822A (en) | 2010-01-14 |
EP2152686B1 (en) | 2014-12-17 |
US20090028952A1 (en) | 2009-01-29 |
DK2152686T3 (en) | 2015-01-12 |
KR20100017483A (en) | 2010-02-16 |
BRPI0810717A2 (en) | 2016-05-24 |
CA2685739A1 (en) | 2008-11-06 |
JP2010526072A (en) | 2010-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2685739C (en) | Hydroxy sulfonate of quinone compounds and their uses | |
EP1877097B1 (en) | Aminoacid conjugates of beta-lapachone for tumor targeting | |
Fröhlich et al. | Synthesis of novel hybrids of thymoquinone and artemisinin with high activity and selectivity against colon cancer | |
da Rocha et al. | Synthesis of new 9-hydroxy-α-and 7-hydroxy-β-pyran naphthoquinones and cytotoxicity against cancer cell lines | |
US8614228B2 (en) | Quinone prodrug compositions and methods of use | |
Kakadiya et al. | Potent DNA-directed alkylating agents: Synthesis and biological activity of phenyl N-mustard–quinoline conjugates having a urea or hydrazinecarboxamide linker | |
US20040266857A1 (en) | Novel lapachone compounds and methods of use thereof | |
WO1999053917A1 (en) | Cannabinoids as antioxidants and neuroprotectants | |
Vue et al. | Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations | |
CA2502975A1 (en) | Chromones and chromone derivatives and uses thereof | |
JP2007517861A (en) | Therapeutic use of quinone derivatives of cannabinoids | |
MX2011004643A (en) | Acenaphtho heterocycle compounds, cyclodextrin inclusion compounds and complexes, and uses in the manufactures of bh3 protein analogue, bcl-2 family protein inhibitors thereof. | |
Dziewulska-Kułaczkowska et al. | Structural studies and characterization of 3-formylchromone and products of its reactions with chosen primary aromatic amines | |
JP6509969B2 (en) | Cyclodextrin carrier-based arteannuin compound complexes and method of preparing the same | |
Rao et al. | Piperazine tethered bergenin heterocyclic hybrids: design, synthesis, anticancer activity, and molecular docking studies | |
Biswas et al. | Single component image guided ‘On-demand’drug delivery system for early stage prostate cancer | |
Zhanga et al. | Synthesis, characterization and antihyperlipidemic of rutin-calcium (II) complex | |
Nagaraj et al. | Synthesis, characterization, molecular modeling, binding energies of β-cyclodextrin-inclusion complexes of quercetin: Modification of photo physical behavior upon β-CD complexation | |
Ma et al. | Phenylspirodrimane with Moderate Reversal Effect of Multidrug Resistance Isolated from the Deep-Sea Fungus Stachybotrys sp. 3A00409 | |
KR20050089007A (en) | Novel lapachone compounds and methods of use thereof | |
Salerno | UNIVERSITAꞌ DEGLI STUDI DI MESSINA | |
BR0304952A (en) | Process of preparing compounds between cyclodextrins or derivatives thereof and antimony or derivatives thereof, from pharmaceutical formulations containing such compounds and associated products, for the treatment of leishmaniasis and schistosomiasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880022708.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08754188 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2685739 Country of ref document: CA Ref document number: 2010506326 Country of ref document: JP Ref document number: MX/A/2009/011822 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3803/KOLNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008246067 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20097024913 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008754188 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008246067 Country of ref document: AU Date of ref document: 20080430 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0810717 Country of ref document: BR Kind code of ref document: A2 Effective date: 20091030 |